At the time of writing, AnaptysBio Inc [ANAB] stock is trading at $23.60, down -1.54%. An important factor to consider is whether the stock is rising or falling in short-term value. The ANAB shares have gain 10.95% over the last week, with a monthly amount glided 17.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
AnaptysBio Inc [NASDAQ: ANAB] stock has seen the most recent analyst activity on June 04, 2025, when H.C. Wainwright upgraded its rating to a Buy but kept the price target unchanged to $38 for it. Previously, Wolfe Research started tracking the stock with Outperform rating on February 04, 2025, and set its price target to $25. On December 11, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $19 on the stock. BTIG Research downgraded its rating to a Neutral. H.C. Wainwright initiated its recommendation with a Buy and recommended $55 as its price target on July 22, 2024. JP Morgan upgraded its rating to Overweight for this stock on July 19, 2024, and upped its price target to $69. In a note dated April 16, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $47 on this stock.
For the past year, the stock price of AnaptysBio Inc fluctuated between $12.21 and $41.31. Currently, Wall Street analysts expect the stock to reach $39.5 within the next 12 months. AnaptysBio Inc [NASDAQ: ANAB] shares were valued at $23.60 at the most recent close of the market. An investor can expect a potential return of 67.37% based on the average ANAB price forecast.
Analyzing the ANAB fundamentals
According to AnaptysBio Inc [NASDAQ:ANAB], the company’s sales were 111.87M for trailing twelve months, which represents an 286.84% jump. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -0.9%, Pretax Profit Margin comes in at -1.26%, and Net Profit Margin reading is -1.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -2.82 and Total Capital is -0.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.18 points at the first support level, and at 22.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.19, and for the 2nd resistance point, it is at 24.79.
Ratios To Look Out For
It is important to note that AnaptysBio Inc [NASDAQ:ANAB] has a current ratio of 8.25. On the other hand, the Quick Ratio is 8.25, and the Cash Ratio is 2.24. Considering the valuation of this stock, the price to sales ratio is 6.20, the price to book ratio is 21.08.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on Dec 30 ’24 when 65184.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on Dec 31 ’24 to buy 13268.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 6646.0 shares on Jan 02 ’25.
